Author/Authors :
Elisa Oricchio، نويسنده , , Gouri Nanjangud، نويسنده , , Andrew L. Wolfe، نويسنده , , Jonathan H. Schatz، نويسنده , , Konstantinos J. Mavrakis، نويسنده , , Man Jiang، نويسنده , , Xiaoping Liu، نويسنده , , Joanne Bruno، نويسنده , , Adriana Heguy، نويسنده , , Adam B. Olshen، نويسنده , , Nicholas D. Socci، نويسنده , , Julie Teruya-Feldstein، نويسنده , , Frances Weis-Garcia، نويسنده , , Wayne Tam، نويسنده , , Rita Shaknovich، نويسنده , , Ari Melnick، نويسنده , , Juha P. Himanen، نويسنده , , R.S.K. Chaganti، نويسنده , , Hans-Guido Wendel، نويسنده ,
Abstract :
Insights into cancer genetics can lead to therapeutic opportunities. By cross-referencing chromosomal changes with an unbiased genetic screen we identify the ephrin receptor A7 (EPHA7) as a tumor suppressor in follicular lymphoma (FL). EPHA7 is a target of 6q deletions and inactivated in 72% of FLs. Knockdown of EPHA7 drives lymphoma development in a murine FL model. In analogy to its physiological function in brain development, a soluble splice variant of EPHA7 (EPHA7TR) interferes with another Eph-receptor and blocks oncogenic signals in lymphoma cells. Consistent with this drug-like activity, administration of the purified EPHA7TR protein produces antitumor effects against xenografted human lymphomas. Further, by fusing EPHA7TR to the anti-CD20 antibody (rituximab) we can directly target this tumor suppressor to lymphomas in vivo. Our study attests to the power of combining descriptive tumor genomics with functional screens and reveals EPHA7TR as tumor suppressor with immediate therapeutic potential.
